Selected article for: "definitive treatment and similar conclusion"

Author: Chun, Seok-Joo; Kim, Jin Ho; Ku, Ja Hyeon; Kwak, Cheol; Lee, Eun Sik; Kim, Suzy
Title: Comparison of radical prostatectomy and external beam radiotherapy in high-risk prostate cancer
  • Cord-id: ss8s1iux
  • Document date: 2021_9_9
  • ID: ss8s1iux
    Snippet: PURPOSE: We evaluated clinical outcomes of high-risk prostate cancer patients receiving external beam radiotherapy (EBRT) or radical prostatectomy (RP). MATERIALS AND METHODS: Patients were classified as high-risk prostate cancer and received definitive treatment between 2005 and 2015. Patients with previous pelvic radiotherapy, positive lymph node or distant metastasis were excluded. The primary outcomes were prostate cancer-specific survival (PCSS) and distant metastasis-free survival (DMFS).
    Document: PURPOSE: We evaluated clinical outcomes of high-risk prostate cancer patients receiving external beam radiotherapy (EBRT) or radical prostatectomy (RP). MATERIALS AND METHODS: Patients were classified as high-risk prostate cancer and received definitive treatment between 2005 and 2015. Patients with previous pelvic radiotherapy, positive lymph node or distant metastasis were excluded. The primary outcomes were prostate cancer-specific survival (PCSS) and distant metastasis-free survival (DMFS). RESULTS: Of 583 patients met the inclusion criteria (77 EBRT and 506 RP), the estimated 10-year PCSS was 97.0% in the RP and 95.9% in the EBRT (p = 0.770). No significant difference was seen in the DMFS (p = 0.540), whereas there was a trend in favor of RP over EBRT in overall survival (OS) (p = 0.068). Propensity score matching analysis with confounding variables was done, with 183 patients (66 EBRT and 117 RP) were included. No significant difference in DMFS, PCSS or OS was found. CONCLUSION: Our data demonstrated similar oncologic PCSS, OS, and DMFS outcomes between EBRT and RP patients.

    Search related documents:
    Co phrase search for related documents
    • adjuvant radiotherapy and locally advanced: 1, 2, 3, 4
    • adjuvant radiotherapy and locoregional recurrence: 1, 2, 3, 4
    • adjuvant radiotherapy and lymph node: 1, 2
    • adjuvant radiotherapy and lymph node metastasis: 1
    • adjuvant treatment and local treatment: 1, 2, 3, 4, 5, 6, 7
    • adjuvant treatment and locally advanced: 1, 2, 3
    • adjuvant treatment and locoregional recurrence: 1
    • adjuvant treatment and lymph node: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
    • adjuvant treatment and lymph node metastasis: 1, 2
    • adjuvant treatment and lymphatic invasion: 1
    • adjuvant treatment and lymphovascular invasion: 1, 2
    • local treatment and locoregional recurrence: 1
    • local treatment and low risk prostate cancer: 1, 2
    • local treatment and lymph node: 1, 2, 3, 4
    • local treatment and lymph node irradiation: 1
    • local treatment and lymph node metastasis: 1
    • local treatment and lymphovascular invasion: 1
    • locally advanced and lymph node: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
    • locally advanced and lymph node metastasis: 1, 2, 3